Research field (4):
Pathobiochemistry
, Pharmacology
, Pharmaceuticals - health and biochemistry
, Structural biochemistry
Research keywords (6):
シャペロン治療
, リソソーム病
, 糖脂質
, Chemical chaperone
, Lysosomal disease
, Glycolipid
Research theme for competitive and other funds (2):
1998 - 2008 Chaperone therapy for Fabry disease
2002 - 2005 Gene therapy for Fabry disease
Papers (20):
Hiroki Maruyama, Kaori Miyata, Mariko Mikame, Atsumi Taguchi, Chu Guili, Masaru Shimura, Kei Murayama, Takeshi Inoue, Saori Yamamoto, Koichiro Sugimura, et al. Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis. Genetics in medicine : official journal of the American College of Medical Genetics. 2019. 21. 8. 1900-1900
Hiroki Maruyama, Kaori Miyata, Mariko Mikame, Atsumi Taguchi, Chu Guili, Masaru Shimura, Kei Murayama, Takeshi Inoue, Saori Yamamoto, Koichiro Sugimura, et al. Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis. Genetics in medicine : official journal of the American College of Medical Genetics. 2019. 21. 2. 512-515
Maruyama H, Taguchi A, Nishikawa Y, Guili C, Mikame M, Nameta M, Yamaguchi Y, Ueno M, Imai N, Ito Y, et al. Medullary thick ascending limb impairment in the GlatmTg(CAG-A4GALT) Fabry model mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2018. 32. 8. 4544-4559
Maruyama H, Miyata K, Mikame M, Taguchi A, Guili C, Shimura M, Murayama K, Inoue T, Yamamoto S, Sugimura K, et al. Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis. Genetics in medicine : official journal of the American College of Medical Genetics. 2018. 21. 1. 44-52